Current Perspective in Agnogenic Myeloid Metaplasia

References

• Raskind W. H., Fialkow P. J. The use of cell markers in the study of human hematopoietic neoplasia. Adv. Cancer Res. 1987; 49: 127–167
   PubMed Web of Science ®Google Scholar
• Jacobson R. J., Salo A., Fialkow P. J. Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189–194
   PubMed Web of Science ®Google Scholar
• Greenberg B. R., Woo L., Veomett I. C., et al. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br. J. Haematol. 1987; 66: 487–490
   PubMed Web of Science ®Google Scholar
• Terui T., Niitsu Y., Mahara K., et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 1990; 75: 1540–1548
   PubMed Web of Science ®Google Scholar
• Martyre M. C., Magdelenat H., Bryckaert M. C., et al. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 1991; 77: 80–86
   PubMed Web of Science ®Google Scholar
• Ignotz R. A., Massague J. Transforming growth factorbeta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 1986; 261: 4337–4345
   PubMed Web of Science ®Google Scholar
• Kimura A., Katoh O., Hyodo H., et al. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br. J. Haematol. 1989; 72: 486–491
   PubMed Web of Science ®Google Scholar
• Reilly J. T., Barnett D., Dolan G., et al. Characterization of an acute micromegakaryocytic leukaemia: Evidence for the pathogenesis of myelofibrosis. Br. J. Haematol. 1993; 83: 58–62
   PubMed Web of Science ®Google Scholar
• Martyré M. C., Romquin N., Le Bousse-Kerdiles M. C., et al. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br. J. Haematol. 1994; 88: 9–16
   PubMed Web of Science ®Google Scholar
• Kimura A., Katoh O., Kuramoto A. Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts. Br. J. Haematol. 1988; 69: 9–12
   PubMed Web of Science ®Google Scholar
• Tefferi A., Hoagland H. C., Therneau T. M., et al. Chronic myelomonocytic leukemia: Natural history and prognostic determinants. Mayo Clin. Proc. 1989; 64: 1246–1254
   PubMed Web of Science ®Google Scholar
• Lambertenghi-Deliliers G., Orazi A., Luksch R., et al. Myelodysplastic syndrome with increased marrow fibrosis: A distinct clinico-pathological entity. Br. J. Haematol. 1991; 78: 161–166
   PubMed Web of Science ®Google Scholar
• Demory J. L., Dupriez B., Fenaux P., et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: A report on 47 cases. Blood 1988; 72: 855–859
   PubMed Web of Science ®Google Scholar
• Reily J. T., Wilson G., Barnett D., Watmore A., Potter A. Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. Br. J. Haematol. 1994; 88: 575–581
   PubMed Web of Science ®Google Scholar
• Rozman C., Giralt M., Feliu E., et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658–2663
   PubMed Web of Science ®Google Scholar
• Silverstein M. N. Agnogenic Myeloid Metaplasia. Publishing Sciences Group, Acton, MA 1975
   Google Scholar
• Visani G., Finelli C., Castelli U., et al. Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients. Br. J. Haematol. 1990; 75: 4–9
   PubMed Web of Science ®Google Scholar
• Tefferi A., Silverstein M. N. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 1994; 86: 893
   PubMed Web of Science ®Google Scholar
• Barosi G., Liberato L. N., Costa A., et al. Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur. J. Haematol. Suppl. 1990; 52: 12–14
   PubMedGoogle Scholar
• Silverstein M. N., ReMine W. H. Splenectomy in myeloid metaplasia. Blood 1979; 53: 515–518
   PubMed Web of Science ®Google Scholar
• Barosi G., Ambrosetti A., Buratti A., et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction. Leukemia 1993; 7: 200–206
   PubMed Web of Science ®Google Scholar
• Tefferi A., Barrett S. M., Silverstein M. N., et al. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am. J. Hematol. 1994; 46: 325–328
   PubMed Web of Science ®Google Scholar
• Silverstein M. N. Control of hypersplenism and painful splenomegaly in myeloid metaplasia by irradiation (editorial). Int. J. Radiat. Oncol. Biol. Phys. 1977; 2: 1221–1222
   PubMed Web of Science ®Google Scholar
• Greenberger J. S., Chaffey J. T., Rosenthal D. S., et al. Irradiation for control of hypersplenism and painful splenomegaly in myeloid metaplasia. Int. J. Radiat. Oncol. Biol. Phys. 1977; 2: 1083–1090
   PubMed Web of Science ®Google Scholar
• Price F., Bell H. Spinal cord compression due to extramedullary hematopoiesis. Successful treatment in a patient with long-standing myelofibrosis. JAMA 1985; 253: 2876–2877
   PubMed Web of Science ®Google Scholar
• Tefferi A., Silverstein M. N., Plumhoff E. A., et al. Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J. Natl. Cancer Inst. 1993; 85: 1520–1522
   PubMed Web of Science ®Google Scholar
• Silverstein M. N., Petitt R. M., Solberg L. A. Anagrelide: A new drug for treating thrombocytosis. N. Engl. J. Med. 1988; 318: 1292–1294
   PubMed Web of Science ®Google Scholar
• Creemers G. J., Lowenberg B., Hagenbeek A. Allogeneic bone marrow transplantation for primary myelofibrosis. Br. J. Haematol. 1992; 82: 772–773
   PubMed Web of Science ®Google Scholar
• Dokal I., Jones L., Deenmamode M., et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Br. J. Haematol. 1989; 71: 158–160
   PubMed Web of Science ®Google Scholar
• Ifrah N., Gardembas-Pain M., Hunault M., et al. Allogeneic bone marrow transplantation for primary myelofibrosis (letter to editor). Br. J. Haematol. 1989; 73: 575–576
   PubMed Web of Science ®Google Scholar